Edition:
India

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

82.68USD
23 May 2018
Change (% chg)

$0.46 (+0.56%)
Prev Close
$82.22
Open
$82.03
Day's High
$82.91
Day's Low
$81.95
Volume
724,826
Avg. Vol
1,360,365
52-wk High
$89.07
52-wk Low
$73.70

Chart for

About

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.... (more)

Overall

Beta: 0.35
Market Cap(Mil.): $95,874.12
Shares Outstanding(Mil.): 1,100.99
Dividend: 0.52
Yield (%): 2.39

Financials

  LLY.N Industry Sector
P/E (TTM): 37.74 30.95 32.75
EPS (TTM): 2.31 -- --
ROI: 8.49 14.84 14.38
ROE: 17.03 16.34 16.07

REFILE-UPDATE 5-Zoetis to buy veterinary diagnostics firm Abaxis for $1.9 bln

* Zoetis says diagnostics should grow faster than animal health

16 May 2018

Lilly to buy cancer drug developer AurKa Pharma

Eli Lilly and Co will buy AurKa Pharma Inc in a deal potentially worth up to $575 million, the U.S. drugmaker said on Monday, seeking access to the privately-held firm's experimental cancer treatment for solid tumors.

14 May 2018

Eli Lilly to buy cancer drug developer AurKa Pharma

May 14 Drugmaker Eli Lilly and Co said on Monday it would buy AurKa Pharma Inc to get access to the privately-held company's experimental cancer treatment for solid tumors.

14 May 2018

Lilly to buy Armo Biosciences for $1.6 billion to bolster cancer pipeline

Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion to expand its portfolio of drugs that helps body's immune system fight cancer as the U.S. drugmaker chases rivals in a lucrative market.

10 May 2018

Lilly to buy Armo Biosciences for $1.6 bln

May 10 Drugmaker Eli Lilly and Co said on Thursday it would buy Armo BioSciences Inc for about $1.6 billion to get access to the drug developer's experimental cancer treatment.

10 May 2018

BRIEF-Elanco Animal Health Announces Addition Of General Counsel

* ELANCO ANIMAL HEALTH - NAMED MICHAEL-BRYANT HICKS AS GENERAL COUNSEL

10 May 2018

BRIEF-Eli Lilly Shareholders Elect The 5 Nominees For Director To 3-Yr Terms Ending In 2021

* ELI LILLY SAYS THE 5 NOMINEES FOR DIRECTOR WERE ELECTED TO SERVE 3-YEAR TERMS ENDING IN 2021 BY VOTING SHAREHOLDERS AT 2018 ANNUAL MEETING - SEC FILING Source text: (http://bit.ly/2jGhwcQ) Further company coverage:

09 May 2018

UPDATE 1-Drugmaker Novo Nordisk beats Q1 profit expectations, nudges up 2018 outlook

* Positive feedback on new Ozempic drug (Adds detail, guidance in Danish crowns)

02 May 2018

BRIEF-Lilly Endowment Reports Open Market Sale Of Shares Of Eli Lilly'S Common Stock

* LILLY ENDOWMENT REPORTS OPEN MARKET SALE OF 178,900 SHARES OF ELI LILLY AND CO'S COMMON STOCK AT AVERAGE PRICE OF $80.85PER SHARE ON APRIL 25 - SEC FILING

26 Apr 2018

FDA panel against higher dose of Lilly-Incyte arthritis drug

An arthritis drug developed by Eli Lilly & Co and Incyte Corp should not be approved at a 4-milligram dose, advisers to the U.S. FDA voted on Monday, in a setback to the drugmakers that were counting on the treatment as a future blockbuster.

24 Apr 2018

Competitors

Earnings vs. Estimates